This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like Regeneron (REGN -1.75%) and Alnylam Pharmaceuticals (ALNY -0.06%). It's a smart play for income investors (3.5% dividend yield) and growth investors alike.
Of course, there are threats and headwinds -- what company doesn't have them? -- but in the video below, Motley Fool health care analysts Michael Douglass and David Williamson reveal why Sanofi (SNY 5.90%) is their favorite European pharma stock.
